|
Solution stability of NDSRI
|
|
7
|
212
|
May 14, 2026
|
|
N-Nitroso Metamizole Impurity C
|
|
4
|
309
|
May 13, 2026
|
|
Development of an Efficient and Scalable Process for Preparing Timolol N-Nitrosamine Impurities B, C, E, H, I, J, and Their ADMET Evaluation -Pub
|
|
2
|
149
|
May 8, 2026
|
|
Adjusting the Preincubation Conditions to Enhance the Ames Test for Detecting the Mutagenicity of N‐Nitrosamines-Pub
|
|
2
|
138
|
May 1, 2026
|
|
Hunt for NDSRIs: Unveiling Hidden Threats with the Novel 15N-Enriched NAP Test-Pub
|
|
3
|
454
|
April 30, 2026
|
|
N-NO formation in 2-mercaptobenzothiazole
|
|
2
|
107
|
April 29, 2026
|
|
EMA's Revision of the Acceptance Limit for N-Nitroso-N-desmethyl-diphenhydramine
|
|
4
|
433
|
April 20, 2026
|
|
Another Prazosin recall linked to N-nitroso-prazosin impurity C raises renewed concern for the finished product
|
|
8
|
545
|
April 20, 2026
|
|
Potential for Nitrosamines in Medical Device Combination Products - Letter to Industry(FDA)
|
|
4
|
171
|
April 20, 2026
|
|
Maximum Daily Dose (MDD) of Cream Formulation
|
|
1
|
163
|
April 17, 2026
|
|
Nitrite in Amines
|
|
14
|
633
|
April 15, 2026
|
|
Stability Assessment of FDA Approved Varenicline Tartrate Products for Critical Quality Attributes – N-Nitroso Varenicline, Solid Form, and Dissolution-Pub
|
|
2
|
99
|
April 14, 2026
|
|
Determination of N-nitroso Caspofungin
|
|
1
|
112
|
March 27, 2026
|
|
Mutagenicity of EAT-positive NDSRIs in HepaRG spheroids-Pub
|
|
0
|
69
|
March 20, 2026
|
|
Minimizing in Source Fragmentation for Mass Spectrometry Based NDSRI Analytical Procedures: A Case Study of Nitroso-bumetanide -Pub
|
|
4
|
314
|
March 19, 2026
|
|
Research on Nitrosamines in Complex Preparations
|
|
2
|
190
|
March 17, 2026
|
|
Testing of N-nitroso-cinacalcet
|
|
8
|
1035
|
March 14, 2026
|
|
Navigating the complexities in characterization of NDSRIs using advanced analytical techniques-Pub
|
|
2
|
239
|
March 12, 2026
|
|
N-nitroso-Duloxetine recall back in the news!
|
|
21
|
4764
|
March 7, 2026
|
|
N-Nitrosodibenzylamine infusion bags
|
|
0
|
121
|
February 27, 2026
|
|
NDSRI growth with respect to age
|
|
11
|
418
|
February 23, 2026
|
|
👨💻 Quantitation of N-Nitrosodimethylamine (NDMA) and N-Nitrosophenylephrine (NNPE) in Phenylephrine Hydrochloride (API) by LC-MS/MS
|
|
0
|
334
|
February 7, 2026
|
|
👨💻 N-Nitroso-Propranolol Test Method & Validation Report
|
|
0
|
156
|
February 7, 2026
|
|
👨💻 N-Nitroso-Methylphenidate Test Method and Validation Report
|
|
0
|
138
|
February 7, 2026
|
|
Ames Concordance with the In Vivo Transgenic Rodent (TGR) Gene Mutation Assay for NDSRIs and Relative In Vivo TGR Potency with Nitrosamines with Robust Dose-Response Carcinogenicity Data-Pub
|
|
1
|
223
|
February 5, 2026
|
|
Available Tools for Prediction of Potential Degradation Products from Nitrosation Reactions
|
|
4
|
277
|
February 4, 2026
|
|
N-nitroso-rivaroxaban amide
|
|
7
|
1967
|
February 4, 2026
|
|
TGA updated Established acceptable intake for nitrosamines in medicines on 29 January 2026
|
|
0
|
390
|
January 29, 2026
|
|
Nitrosamine Drug Substance-Related Impurities cause DNA methylation adducts in vitro and in primary hepatocytes upon Cytochrome P450-dependend metabolic activation-Pub
|
|
2
|
235
|
January 29, 2026
|
|
Sufentanil Nitroso impurity standard
|
|
8
|
235
|
January 29, 2026
|